USOR 23251 - STAR Ph3 AZD5305 with HR+ HER2 negative advanced breast cancer (EvoPAR-Breast01)

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer

Disease Types: STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Chicago Resurrection, Niles